Loading organizations...
§ Private Profile · Conshohocken, PA, USA
Clinical-stage pharmaceutical company developing novel osteoporosis treatments, including a teriparatide nasal spray.
Azelon Pharmaceuticals is a clinical-stage specialty pharmaceutical company based in West Conshohocken, Pennsylvania, that develops novel treatments for osteoporosis, including a proprietary nasal spray formulation of teriparatide. The biotechnology firm raised more than $75 million in total funding throughout its operational history to finance its research and development efforts. This capital included a $27 million Series A financing round secured in November 2012 to fund Phase 2 clinical trials for its primary bone mass therapeutic candidate. The enterprise was backed by a syndicate of prominent venture capital and investment firms, including Domain Associates, NovaQuest Capital Management, Alta Partners, and GlaxoSmithKline’s SR One. Following the announcement of Phase 2b clinical trial results in late 2013, the business became inactive in the public domain. Originally founded in 2000, the specific names of the company's creators remain publicly undisclosed.
Azelon Pharmaceuticals has raised $4.5M across 1 funding round.
Azelon Pharmaceuticals has raised $4.5M in total across 1 funding round.
Azelon Pharmaceuticals has raised $4.5M in total across 1 funding round.
Azelon Pharmaceuticals's investors include Alex Barkas, Covington Venture Fund, Lighthouse Capital Partners.
Azelon Pharmaceuticals has raised $4.5M across 1 funding round. Most recently, it raised $4.5M Series A in October 2011.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Oct 11, 2011 | $4.5M Series A | Alex Barkas | Covington Venture Fund, Lighthouse Capital Partners | Announced |